Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell Support
Fate Therapeutics, Inc. announced that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate.
[Read the full article here]Related News:
Fate Therapeutics Announces First Patient Treated In Phase 1b Clinical Trial Of FT1050 For Hematopoietic Stem Cell …
First Patient Treated In Osiris Phase II Stem Cell Trial For Heart Attacks
Athersys Announces Positive Results of MultiStem Clinical Trial for Hematopoietic Stem Cell Transplant Support and …